Literature DB >> 14596665

Toll-like receptor signalling pathways as key targets for mediating the anti-inflammatory and immunosuppressive effects of glucocorticoids.

P N Moynagh1.   

Abstract

Toll-like receptors (TLRs) play crucial roles in the induction of innate immune responses by recognising pathogen-associated molecular patterns. The engagement of TLRs by pathogens results in induction of co-stimulatory molecules that facilitate a specific immune response and also in the induction of pro-inflammatory proteins that will promote the elimination of pathogens from the body. TLRs employ many of the same signalling components as the type I interleukin (IL)-1 receptor (IL-1R). This is hardly surprising since the intracellular regions of TLRs and the IL-1R share a conserved Toll/IL-1R homology domain (TIR) that allows the receptors to recruit the intracellular TIR-containing adaptor protein Myd88. The latter then activates IL-1R-associated kinases that in turn recruit well-characterised downstream effectors culminating in activation of MAP kinases and transcription factors such as NFkappaB and AP-1. Since glucocorticoids are known to target the latter transcription factors and the MAP kinase cascades, this commentary highlights the likely crucial importance of Toll-like receptor signalling pathways as key targets for mediating the anti-inflammatory and immunosuppressive effects of steroids.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14596665     DOI: 10.1677/joe.0.1790139

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  17 in total

Review 1.  From the Th1/Th2 paradigm towards a Toll-like receptor/T-helper bias.

Authors:  Mihai G Netea; Jos W M Van der Meer; Roger P Sutmuller; Gosse J Adema; Bart-Jan Kullberg
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 2.  Pathogen recognition and inflammatory signaling in innate immune defenses.

Authors:  Trine H Mogensen
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

Review 3.  Cytokines as biomarkers of nanoparticle immunotoxicity.

Authors:  Mahmoud Elsabahy; Karen L Wooley
Journal:  Chem Soc Rev       Date:  2013-06-21       Impact factor: 54.564

4.  Activation of inflammatory immune gene cascades by lipopolysaccharide (LPS) in the porcine colonic tissue ex-vivo model.

Authors:  B Bahar; J V O'Doherty; S Vigors; T Sweeney
Journal:  Clin Exp Immunol       Date:  2016-08-02       Impact factor: 4.330

Review 5.  Modeling intraocular bacterial infections.

Authors:  Roger A Astley; Phillip S Coburn; Salai Madhumathi Parkunan; Michelle C Callegan
Journal:  Prog Retin Eye Res       Date:  2016-05-03       Impact factor: 21.198

6.  Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses.

Authors:  Weikang Tao; Xianzhi Mao; Joseph P Davide; Bruce Ng; Mingmei Cai; Paul A Burke; Alan B Sachs; Laura Sepp-Lorenzino
Journal:  Mol Ther       Date:  2010-12-21       Impact factor: 11.454

7.  Toll-like receptors 2, 3 and 4 (TLR-2, TLR-3 and TLR-4) are expressed in the microenvironment of human acquired cholesteatoma.

Authors:  Mirosław Szczepański; Witold Szyfter; Renata Jenek; Maciej Wróbel; Iwona Mozer Lisewska; Jan Zeromski
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-03-15       Impact factor: 2.503

8.  Anti-inflammatory treatment strategies for ischemia/reperfusion injury in transplantation.

Authors:  Jens Lutz; Klaus Thürmel; Uwe Heemann
Journal:  J Inflamm (Lond)       Date:  2010-05-28       Impact factor: 4.981

9.  Can postpyelonephritic renal scarring be prevented?

Authors:  Tryggve Nevéus
Journal:  Pediatr Nephrol       Date:  2012-10-20       Impact factor: 3.714

10.  Mechanisms of dexamethasone-mediated inhibition of Toll-like receptor signaling induced by Neisseria meningitidis and Streptococcus pneumoniae.

Authors:  Trine H Mogensen; Randi S Berg; Søren R Paludan; Lars Østergaard
Journal:  Infect Immun       Date:  2007-10-15       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.